Work

Nivolumab plus temozolomide (Nivo/Tem) vs. temozolomide monotherapy in refractory melanoma.

Year: 2026

Type: article

Study design: Observational Study

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.e21507

Authors: Preethy Abraham, Sheau-Chiann Chen, Kun Bai, Douglas Buckner Johnson

Institutions: Vanderbilt University, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162692269

FWCI:

Cites:

Cited by:

Related to: